



**University of
Zurich^{UZH}**

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2015

Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome

Buder, Kathrin ; Latal, Beatrice ; Nef, Samuel ; Neuhaus, Thomas J ; Laube, Guido F ; Spartà, Giuseppina

Abstract: **BACKGROUND** To investigate the long-term neurodevelopmental outcome in children after hemolytic uremic syndrome (HUS) and to compare outcome dependent on central nervous system (CNS) involvement during HUS. **METHODS** A single-center retrospective cohort of 47 children was examined at a median age of 10.6 (range 6-16.9) years and a median follow-up of 7.8 (range 0.4-15.3) years after having had HUS. Intellectual performance was assessed with the German version of the Wechsler Intelligence Scale 4th version and neuromotor performance with the Zurich Neuromotor Assessment (ZNA). The occurrence of neurological symptoms during the acute phase of HUS was evaluated retrospectively. **RESULTS** Mean IQ of the whole study population fell within the normal range (median full scale IQ 104, range 54-127). Neuromotor performance was significantly poorer in the domains "adaptive fine," "gross motor," "static balance" (all $p < 0.05$) and "associated movements" ($p < 0.001$); only the "pure motor" domain was within the normal reference range. Neurological findings occurred in 16/47 patients (34 %) during acute HUS. Neurodevelopmental outcome was not significantly different between children with or without CNS involvement. **CONCLUSIONS** Our follow-up of children after HUS showed a favorable cognitive outcome. However, neuromotor outcome was impaired in all study participants. Neurological impairment during acute HUS was not predictive of outcome.

DOI: <https://doi.org/10.1007/s00467-014-2950-0>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-118973>

Journal Article

Published Version

Originally published at:

Buder, Kathrin; Latal, Beatrice; Nef, Samuel; Neuhaus, Thomas J; Laube, Guido F; Spartà, Giuseppina (2015). Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome. *Pediatric Nephrology*, 30(3):503-513.

DOI: <https://doi.org/10.1007/s00467-014-2950-0>

Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome

Kathrin Buder · Beatrice Latal · Samuel Nef ·
Thomas J. Neuhaus · Guido F. Laube ·
Giuseppina Sparta

Received: 7 May 2014 / Revised: 22 August 2014 / Accepted: 25 August 2014 / Published online: 19 September 2014
© IPNA 2014

Abstract

Background To investigate the long-term neurodevelopmental outcome in children after hemolytic uremic syndrome (HUS) and to compare outcome dependent on central nervous system (CNS) involvement during HUS.

Methods A single-center retrospective cohort of 47 children was examined at a median age of 10.6 (range 6–16.9) years and a median follow-up of 7.8 (range 0.4–15.3) years after having had HUS. Intellectual performance was assessed with the German version of the Wechsler Intelligence Scale 4th version and neuromotor performance with the Zurich Neuromotor Assessment (ZNA). The occurrence of neurological symptoms during the acute phase of HUS was evaluated retrospectively.

Results Mean IQ of the whole study population fell within the normal range (median full scale IQ 104, range 54–127). Neuromotor performance was significantly poorer in the domains “adaptive fine,” “gross motor,” “static balance” (all $p < 0.05$) and “associated movements” ($p < 0.001$); only the “pure motor” domain was within the normal reference range. Neurological findings occurred in 16/47 patients (34 %) during acute HUS. Neurodevelopmental outcome was not significantly different between children with or without CNS involvement.

Conclusions Our follow-up of children after HUS showed a favorable cognitive outcome. However, neuromotor outcome was impaired in all study participants. Neurological impairment during acute HUS was not predictive of outcome.

Keywords Intellectual · Motor · Neurocognitive outcome · Central nervous system involvement · Hemolytic uremic syndrome

Introduction

Hemolytic uremic syndrome (HUS) is a multi-organ and life-threatening disease characterized by hemolytic anemia, thrombocytopenia and acute renal injury. HUS is also one of the most frequent causes of acute renal failure in childhood [1] and may result in long-term renal and extrarenal sequelae [2–5].

About 90 % of HUS cases in childhood are infection-induced, i.e. they are typical HUS forms, mainly mediated by infections caused by Shiga toxin-producing bacteria, usually enterohemorrhagic *Escherichia coli* (STEC-HUS) but in some regions *Shigella dysenteriae* type 1. In addition, infections with *Streptococcus pneumoniae* (P-HUS) and other bacterial and viral agents can trigger HUS [6, 7]. Only 5–10 % of cases are defined as atypical HUS (aHUS) based on various hereditary and/or acquired disorders of the alternative complement pathway regulation [6–8]. Renal replacement therapy at disease onset is required in up to 65 % of STEC-HUS patients [9], 84 % of those with P-HUS [10] and 59 % of aHUS patients [5].

Extrarenal manifestations are frequent in all HUS forms, including STEC-HUS [11, 12], P-HUS [13, 14] and aHUS [5, 15], and may affect the central nervous system (CNS), gastrointestinal tract, heart, eyes, lungs, parotid glands and skin.

K. Buder · S. Nef · G. F. Laube · G. Sparta (✉)
Pediatric Nephrology Unit, University Children's Hospital, Zurich,
Steinwiesstrasse 75, 8032 Zurich, Switzerland
e-mail: giuseppina.sparta@kispi.uzh.ch

B. Latal
Child Development Center, University Children's Hospital, Zurich,
Steinwiesstrasse 75, 8032 Zurich, Switzerland

T. J. Neuhaus
Children's Hospital of Lucerne, Cantonal Hospital of Lucerne,
6000 Lucerne 16, Switzerland

CNS involvement represents a major complication that is associated with increased mortality [2, 11] and risk for neurological sequelae [16].

Studies reporting on neurodevelopmental outcome in children after HUS are scarce, and the results suggest a normal neurocognitive outcome [17–19]. However, a trend towards impaired full-scale and verbal comprehension IQ in these children has also been described [17]. Data on neuromotor outcome are limited to information on impaired fine motor skills in children with a history of HUS and severe CNS involvement [18].

In the study reported here, we focused on the long-term intellectual and neuromotor performance in a single-center cohort of children after HUS, including typical and atypical HUS forms. The hypothesis was that all children with HUS may have a higher risk for adverse neurodevelopmental outcome. Furthermore, the study was performed to determine the influence of CNS involvement during acute HUS disease on the long-term neurodevelopmental outcome.

Methods

Patients

The study cohort consisted of 47 children (22 males, 25 females; median age 10.6 years, age range 6–16.9 years) with a history of both typical infection-induced HUS and atypical HUS. The neurodevelopmental testing was part of a comprehensive single-center study on long-term renal outcome, psychological adjustment and quality of life in HUS patients. The study was approved by the Cantonal Ethics Committee Zurich and registered at ClinicalTrials.gov (NCT 01666548). Written informed consent was obtained by the parents and by the adolescents themselves if they were ≥ 15 years. Inclusion criteria for neurocognitive and neuromotor assessment were: (1) previous diagnosis of HUS and (2) age between 6 years and 16 years 11 months during the study period between February 2012 and February 2013.

HUS was defined as non-immunological hemolytic anemia (hemoglobin < 100 g/l), thrombocytopenia (thrombocytes $< 150,000/\mu\text{l}$) and features of acute renal injury (plasma creatinine elevation above the age-related norm range; proteinuria, hematuria or renal ultrasound abnormalities). Two of the enrolled patients—one with STEC-HUS requiring dialysis and one with recurrent aHUS due to complement factor H mutation—did not meet the criteria for thrombocytopenia. The diagnosis of HUS in all patients was confirmed by pediatric nephrologists. Based on the different approaches used in published studies to classify HUS [20–22] we categorized the disease as (1) typical, infection-induced HUS, including STEC-HUS and P-HUS, and (2) aHUS based on currently proposed HUS nomenclature [21].

The age criterion of 6–16 years was used to study long-term neurocognitive outcome using one intellectual test, namely, the German version of the *Wechsler Intelligence Scale 4th version* [23].

Participants were recruited from a sample of 129 patients treated for HUS at the Pediatric Nephrology Unit of Zurich University Children's Hospital between April 1995 and February 2013. Seven patients died during an acute episode of HUS, five patients were lost to follow-up and 42 patients did not fulfil the age criterion (26 were aged < 6 years and 16 were aged ≥ 17 years). Thus, 75 patients were eligible for the study. Twenty-six parents or children refused to participate; two additional patients were excluded due to a pre-existing neurodevelopmental impairment resulting from trisomy 21 in one and an unclassified syndrome in another. The final study cohort included 47 (63 %) of the children originally eligible for entry. Demographic and clinical characteristics did not differ significantly between enrolled patients and those not enrolled in terms of sex, HUS form, socioeconomic status, age at diagnosis of HUS, frequency of neurological complications during the acute phase of HUS, occurrence of anuria, need for dialysis during the acute phase of HUS, length of hospital stay, estimated glomerular filtration rate (eGFR) at time of discharge, need of dialysis at time of discharge and development of end-stage renal disease (ESRD).

The clinical and demographic data needed to evaluate potential risk factors were extracted from patients' records and analyzed retrospectively. Values for the following parameters were obtained from the medical records: sex, age at disease onset, renal function, anuria defined as urine output < 0.2 ml/kg per hour, requirement of dialysis and CNS involvement during the acute episode of HUS. CNS involvement was defined as presence of neurological findings including seizures, altered consciousness, ataxia, muscle tone abnormalities, hemiplegic symptoms, dysarthria, visual disorders, movement disorders and vestibular symptoms. Since conditions such as anemia or dehydration may affect mental status, CNS involvement was only considered if the clinical symptoms were severe and not attributable to an underlying non-cerebral medical condition. None of the studied children had a neurological disease prior to HUS.

Other comorbidities and ESRD with renal replacement therapy at follow-up were also recorded. Renal function was evaluated by eGFR, expressed in milliliters per minute per 1.73 m^2 , according to the Schwartz formula using the local factor k of 40 for all children and by the plasma creatinine concentration (in $\mu\text{mol/l}$) [24]. Information on additional potential neurological risk factors and interventions performed since HUS was retrieved from parental interviews at the time of neurodevelopmental assessment.

Neurodevelopmental outcome assessment

The neurodevelopmental outcome assessment included as assessment of intellectual and neuromotor performance and a standardized neurological examination [25]; both were performed at the Child Development Center of Zurich University Children's Hospital by one experienced developmental pediatrician. Socioeconomic status was estimated based on maternal education level and paternal occupation using an education scale ranging from 2 to 12, with 2 being the lowest and 12 the highest education score [26].

Intellectual performance

Of the 47 participants, 46 were assessed using with the German version of the *Wechsler Intelligence Scale 4th version* [23]. This test provides IQ subscales for verbal comprehension, perceptual reasoning, working memory and processing speed, which together form the full-scale IQ. One 9-year-old patient with P-HUS associated with meningitis and serious neurological complications was not able to perform the *Wechsler Intelligence Scale 4th version* and was examined using the German version of the *Wechsler Preschool and Primary Scale of Intelligence 3rd version* [27].

Neuromotor performance

Neuromotor performance was examined with the Zurich Neuromotor Assessment (ZNA), a standardized, videotaped test for children aged 5 to 18 years which is used to investigate specific motor skills based on timed performances and movement quality [28, 29]. The ZNA contains five block components including: (1) pure motor domain, (2) adaptive fine motor domain, (3) adaptive gross motor domain, (4) static balance and (5) associated movements. The results are expressed as *z*-scores, i.e. the standard score of the reference population based on age and sex.

Statistical analysis

Statistical analysis was performed with SPSS for Windows version 20.0 and 22.0 (IBM Corp., New York, NY). Differences between participants' data and normative data were calculated using the univariate *t* test, and differences between subgroups were assessed using the Mann–Whitney *U* test for continuous variables and Fisher's exact test for categorical variables. Multivariate linear regression was conducted to evaluate the association between risk factors and full-scale IQ scores. Variables included in the regression model were socioeconomic status, duration of hospital stay, CNS involvement and eGFR at time of discharge. Two children with very low full-scale IQ scores (54 and 62) were excluded for the multiple regression analysis in order to comply with the

requirements of a normal distribution in the study sample. A *p* value of <0.05 was considered to be statistically significant.

Results

Sample description

Forty-seven patients (22 boys and 25 girls; median age 10.6 years, range 6–16.9 years) with a history of STEC–HUS (*n*=38), P-HUS (*n*=6) and aHUS (*n*=3) and a median follow-up after HUS of 7.8 (range 0.4–15.3) years participated in this study (for detailed information on each participant, see Table 1).

Of the 38 STEC-HUS patients, 24 tested positive for Shiga toxin. Genetic analysis of the three aHUS patients revealed one or more mutations of complement-related factors. The median age at onset of HUS was 1.8 (range 0.3–14.4) years. Thirty-three children (70 %) required acute renal replacement therapy combined with either peritoneal dialysis (*n* = 24 patients), hemofiltration or hemodialysis (*n* = 6) or a combination of both treatment modalities (*n* = 3). At time of discharge the median eGFR was 54 (range 13–178) ml/min per 1.73 m². Forty-one (87 %) patients had an impaired eGFR defined as <90 ml/min per 1.73 m². One patient was on dialysis when discharged and remained on dialysis for 127 days, subsequently progressing to ESRD. Five patients developed ESRD, of whom four underwent renal transplantation (RTPL) (Table 1).

The median eGFR at neurodevelopmental testing—excluding the four children who underwent RTPL—was 113 (range 12–178) ml/min per 1.73 m²; ten of these children had impaired renal function with an eGFR of <90 (range 12–88) ml/min per 1.73 m². Two of the four patients undergoing RTPL had good renal graft function defined as an eGFR of >60 (respectively 92 and 163) ml/min per 1.73 m², while the remaining two children showed impaired graft function (47 and 54 ml/min per 1.73 m², respectively). The children with CNS involvement has a significantly lower median eGFR at both discharge and follow-up (46 and 89 ml/min per 1.73 m², respectively; *p*=0.014) than the children without CNS involvement (83 and 126 ml/min per 1.73 m², respectively; *p*=0.004) (Table 2).

CNS involvement during acute episode of HUS

Sixteen children (34 %) presented with CNS involvement during the acute episode of HUS with a broad spectrum of neurological symptoms, consisting predominantly of seizures (12/16) or altered consciousness (7/16) (Table 3).

In the STEC-HUS group neurological symptoms were observed in 12 of 38 patients. Two children received treatment with plasmapheresis due to severe neurological complications (Table 1). Four of the six P-HUS patients presented with neurological symptoms, including two with pneumococcal meningitis. None of the patients with aHUS manifested CNS

Table 1 Characterization of all 47 study participants according to hemolytic uremic syndrome form

Patient	Diagnosis ^a	Neurological symptoms during acute HUS	Radiological findings during acute HUS ^b	Additional neurological risk factors	Full scale IQ (Wechsler Intelligence Scale 4th version)	Renal outcome (eGFR; ml/min per 1.73 m ²) ^c
1	STEC-HUS	Seizure	CCT: normal	–	110	113
2	STEC-HUS	–	NI	Attention deficit hyperactivity disorder	88	167
3	STEC-HUS	–	NI	–	99	95
4	STEC-HUS	–	NI	–	108	126
5	STEC-HUS	–	NI	–	104	111
6	STEC-HUS	–	NI	–	104	102
7	STEC-HUS	Seizure	CCT: normal	–	98	88
8	STEC-HUS	Seizure	NI	–	109	133
9	STEC-HUS	–	NI	–	102	172
10	STEC-HUS	–	NI	–	112	79
11	STEC-HUS	Seizure	CCT: normal	–	105	100
12	STEC-HUS	Seizure	NI	Resuscitation (mechanical)	105	139
13 ^d	STEC-HUS	Seizure, ataxia, movement disorder, dysarthria	CCT, CMRI: basal ganglia infarctions/ischemias	–	108	53
14	STEC-HUS	–	NI	–	101	105
15	STEC-HUS	Altered consciousness	NI	–	104	78
16	STEC-HUS	–	NI	–	101	135
17	STEC-HUS	Seizure, altered consciousness	CCT: not specific	–	105	74
18	STEC-HUS	Seizure, altered consciousness	CCT: normal, CMRI: multiple infarctions	–	103	12 (ESRD)
19	STEC-HUS	–	NI	–	115	112
20	STEC-HUS	–	NI	–	105	178
21	STEC-HUS	–	NI	–	105	131
22	STEC-HUS	–	NI	–	118	171
23	STEC-HUS	–	NI	–	84	47 (Status after RTPL)
24	STEC-HUS	–	NI	–	108	103
25	STEC-HUS	–	NI	–	103	175
26	STEC-HUS	–	NI	–	127	94
27	STEC-HUS	–	NI	–	99	54 (Status after RTPL)
28	STEC-HUS	–	NI	–	99	147
29	STEC-HUS	–	NI	–	102	83
30	STEC-HUS	–	NI	–	121	133
31	STEC-HUS	–	NI	Prematurity (31 4/7 gestational age)	82	126
32	STEC-HUS	–	NI	–	109	107
33 ^d	STEC-HUS	Seizure, altered consciousness, visual disorder, ataxia, vestibular symptoms	CCT, CMRI: normal	–	127	72

Table 1 (continued)

Patient	Diagnosis ^a	Neurological symptoms during acute HUS	Radiological findings during acute HUS ^b	Additional neurological risk factors	Full scale IQ (Wechsler Intelligence Scale 4th version)	Renal outcome (eGFR; ml/min per 1.73 m ²) ^c
34	STEC-HUS	–	NI	–	102	139
35	STEC-HUS	–	NI	–	96	141
36	STEC-HUS	–	NI	–	110	128
37	STEC-HUS	Altered consciousness	NI	–	105	90
38	STEC-HUS; sepsis due to <i>Streptococcus pneumoniae</i>	Seizure, muscle tone abnormality	CCT: not specific	–	100	72
39	P-HUS (pneumonia)	Hemiplegic symptoms	CCT: normal; CMRI: leukoencephalopathy	–	75	92 (Status after RTPL)
40	P-HUS (meningitis)	Seizure, hemiplegic symptoms	CCT: subdural empyema, ischemic changes, hydrocephalus	Sensorineural hearing loss, cochlear implant	90	116
41	P-HUS (pneumonia)	–	NI	–	75	146
42	P-HUS (pneumonia, peritonitis)	–	NI	–	109	129
43	P-HUS (pneumonia)	Ataxia, altered consciousness	CCT: not specific	–	91	141
44	P-HUS (meningitis)	Seizure, ataxia, altered consciousness, muscle tone abnormality	CCT: meningoencephalitis, subdural hygroma; CMRI: leukoencephalo-malacia, hydrocephalus internus, signs of intra-cranial hypertension	Ventriculoperitoneal shunt implant, sensorineural hearing loss, cochlear implant, transient symptomatic epilepsy	62 ^f	77
45	aHUS (CFH mutation, one clinical relapse, no complement activity)	–	NI	–	125	126
46 ^e	aHUS (DEAP-HUS, ongoing complement activity)	–	NI	–	126	113
47	aHUS (combined MCP and CFI mutation, one clinical relapse leading to ESRF)	–	NI	Resuscitation (mechanical & medical), viral meningitis	54	163 (Status after RTPL)

^a HUS, Hemolytic uremic syndrome; STEC-HUS, *Escherichia coli* hemolytic uremic syndrome; P-HUS, *Streptococcus pneumoniae* hemolytic uremic syndrome; aHUS, atypical hemolytic uremic syndrome; DEAP-HUS, deficiency of complement factor H-related plasma proteins and autoantibody-positive form of hemolytic uremic syndrome; MCP, membrane cofactor protein CD46; CFH, complement factor H; CFI, complement factor I; ESRF, end-stage renal failure

^b CCT, Cerebral computed tomography; CMRI, cerebral magnetic resonance imaging; NI, not investigated

^c eGFR, Estimated glomerular filtration rate; RTPL, renal transplantation

^d Treatment with plasmapheresis during acute HUS

^e Treatment with plasmapheresis because of complement factor H antibodies (no cerebral impairment)

^f The patient was not able to perform the Wechsler Intelligence Scale 4th version and was therefore examined with the German version of the Wechsler Preschool and Primary Scale of Intelligence 3rd version

Table 2 Demographic and clinical characteristics of the 47 hemolytic uremic syndrome (HUS) patients enrolled in the study

Demographic and clinical characteristics	CNS involvement during acute episode of HUS (<i>n</i> =16)	No CNS involvement during acute episode of HUS (<i>n</i> =31)	<i>p</i> value
General data			
Sex: male/female (<i>n</i>)	6/10	16/15	0.54
HUS-classification (<i>n</i>)			
STEC-HUS	12	26	
P-HUS	4	2	
aHUS	0	3	
Socioeconomic status score	8 (7–12)	8 (2–12)	0.38
Acute episode of HUS			
Age (years)	1.3 (0.3–14.4)	2.2 (0.4–13.3)	0.24
Anuria (<i>n</i>)	14	14	0.006*
Duration of anuria (days)	8 (1–46)	9 (2–20)	0.58
Dialysis (<i>n</i>)	14	19	0.09
Duration of dialysis (days)	13 (5–79)	11 (3–23)	0.18
Mode of dialysis			
Peritoneal dialysis (<i>n</i>)	9	14	
Hemofiltration/hemodialysis (<i>n</i>)	4	2	
Combination of peritoneal dialysis and hemofiltration/hemodialysis (<i>n</i>)	1	3	
Duration of hospital stay (days)	26 (10–97)	16 (5–54)	0.030*
eGFR at discharge (ml/min per 1.73 m ²)	46 (13–125)	83 (14–178)	0.014*
Dialysis at discharge (<i>n</i>)	1	0	0.34
Follow-up			
Age (years)	11.1 (6.3–16.3)	10.4 (6.0–16.9)	0.50
Time interval HUS to follow-up (years)	9.1 (0.6–15.3)	7.2 (0.4–15.1)	0.27
Development of ESRD (<i>n</i>)	2	3	1.00
Duration of dialysis in total (acute and chronic) (days)	13 (5–218)	12 (3–1560)	0.65
Status after RTPL (<i>n</i>)	1	3	1.00
eGFR at neurodevelopmental examination (ml/min per 1.73 m ²)	89 (12–141)	126 (47–178)	0.004*

*Significant difference at $p < 0.05$

Results are presented as the median with the range in parenthesis

CNS, Central nervous system; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; RTPL, renal transplant; STEC-HUS, *Escherichia coli* hemolytic uremic syndrome; P-HUS, *Streptococcus pneumoniae* hemolytic uremic syndrome; aHUS, atypical hemolytic uremic syndrome

involvement, but one was resuscitated due to respiratory failure following RTPL.

Neuroimaging studies were performed in 12 of 16 patients with CNS involvement (cerebral computed tomography in 7, cerebral magnetic resonance imaging in 5 and both investigations in 5 children), revealing cerebral abnormalities in five patients: two with cerebral infarctions (both STEC-HUS), two with meningitis-associated complications and one child with leukoencephalopathy (P-HUS) (Table 1).

Comparison of clinical and demographic characteristics between participants without and with CNS involvement during the acute episode of HUS showed that anuria ($p=0.006$), longer duration of hospital stay ($p=0.03$) and impaired eGFR, both at discharge ($p=0.01$) and at time of neurodevelopmental testing ($p=0.004$), were significantly more common in patients with CNS impairment (Table 2).

Additional comorbidities, not HUS related and potentially leading to neurodevelopmental impairment, were present in four children, with one child each having status after viral meningitis and resuscitation for pulmonary edema after RTPL, resuscitation associated with an anesthetic accident, prematurity and attention deficit hyperactivity disorder treated with methylphenidate, respectively. Two additional children with P-HUS developed severe cerebral complications (Table 1): subdural empyema and hydrocephalus, respectively.

Intellectual performance

The median full-scale IQ of the study cohort was normal with a value of 104 {54–127 points; comparison to norm of 100 [$\pm 15=1$ standard deviation (SD)]: $p=0.39$ }. All subscales were in the normal range: verbal comprehension [102 (range

Table 3 Neurological symptoms of the 16 patients enrolled in the study with CNS involvement during acute HUS

Neurological symptoms	Frequency
Seizures	12/16
Isolated seizures	5/16
Altered consciousness	7/16
Isolated altered consciousness	2/16
Ataxia	4/16
Muscle tone abnormality	2/16
Hemiplegic symptoms	2/16
Dysarthria	1/16
Visual disorders	1/16
Movement disorders	2/16
Vestibular symptoms	1/16
>1 neurological symptoms	8/16
Number of neurological symptoms	
1	8/16
2	5/16
3	0/16
4	1/16
5	2/16

Results are presented as the number of patients

CNS, Central nervous system; HUS, hemolytic uremic syndrome

69–130); $p=0.57$], working memory [102 (54–144); $p=0.52$], processing speed [100 (65–129); $p=0.69$] and perceptual reasoning [108 (61–129); $p=0.03$].

Six children (13 %) showed a full-scale IQ of <85 (-1 SD). Two of these two patients had a full-scale IQ of <70 (-2 SD)—one with P-HUS and pneumococcal meningitis and multiple complications requiring ventriculoperitoneal shunt and cochlear implant and the second with a past history of resuscitation episode, aHUS and ESRD in infancy (Table 1).

Children with a history of ESRD showed a poorer neurocognitive outcome than children without ESRD in terms of verbal comprehension [88 (range 69–95) vs. 105 (79–130); $p=0.004$], working memory [87 (54–102) vs. 102 (74–144); $p=0.008$] and full-scale IQ [84 (54–103) vs. 105 (62–127); $p=0.010$].

There were no significant differences between the 16 individuals with and the 31 individuals without CNS involvement during the acute phase of HUS (Table 4). Socioeconomic status did not differ between these two groups (Table 2). Furthermore, the exclusion of patients with neurodevelopmental comorbidities ($n=6$) and those with development of ESRD ($n=5$) did not significantly alter the results of the intellectual outcome.

Neuromotor performance

Forty-seven children (22 boys, 25 girls) performed the ZNA. Except for the pure motor domain, all other domains of the neuromotor performance were significantly impaired compared to the normal controls (Table 5). Between 15 and 38 % of the children performed poorer than the 10th percentile within the five ZNA domains (Table 5).

Table 4 Intellectual performance^a of the 16 children with and 31 children without CNS involvement during the acute episode of HUS ($n=47$)

Full-scale and subscale IQ	CNS involvement during acute episode of HUS ($n=16$) ^b	No CNS involvement during acute episode of HUS ($n=31$)	p -value
Full-scale IQ	105 (62–127) ^b	104 (54–127)	0.62
Verbal comprehension index	99 (81–124)	103 (69–130)	0.49
Similarities	11 (6–14)	12 (4–17)	0.51
Vocabulary	10 (5–15)	10 (3–14)	0.76
Comprehension	9 (6–16)	10 (7–19)	0.31
Perceptual reasoning index	108 (81–117)	108 (61–129)	0.81
Block design	12 (5–16) ^b	12 (5–18)	0.74
Picture concepts	10 (6–14)	10 (2–13)	0.84
Matrix reasoning	11 (8–14)	11 (2–18)	0.90
Working memory index	102 (56–135)	102 (54–144)	0.98
Digit span	10 (3–16)	10 (3–16)	0.78
Arithmetic	10 (2–17)	11 (1–19)	0.60
Processing speed index	96 (71–129) ^b	103 (65–129)	0.29
Coding	9 (4–14) ^b	10 (4–14)	0.40
Symbol search	10 (5–16) ^b	12 (3–16)	0.40

Results are presented as the median IQ score, with the range in parenthesis

CNS, Central nervous system; HUS, hemolytic uremic syndrome

^a Intellectual performance was assessed using the *Wechsler Intelligence Scale 4th version*

^b One patient (Table 1, patient no. 44) was not able to perform the *Wechsler Intelligence Scale 4th version* except the subtests “Block design”, “Coding” and “Symbol Search.. His results are only included in the subtests, processing speed index and full scale IQ

Table 5 Motor performance^a data of all patients ($n=47$) and of the 16 children with and 31 children without central nervous system (CNS) involvement during the acute episode of hemolytic uremic syndrome (HUS)

Zurich Neuromotor Assessment domains	All patients			CNS involvement during acute episode of HUS (<i>n</i> =16)	No CNS involvement during acute episode of HUS (<i>n</i> =31)	<i>p</i> value ^d
	<i>z</i> -score	<P10 ^b	<i>p</i> value ^c			
Timed performances						
Pure motor	0.10 (−5.5 to 4.6)	15 % (7/47)	0.73	0.25 (−5.5 to 1.7)	0.10 (−2.4 to 4.6)	0.65
Adaptive fine motor	−0.30 (−3.6 to 3.5)	28 % (13/46)	0.042*	−0.23 (−2.7 to 1.2)	−0.30 (−3.6 to 3.5)	0.72
Adaptive gross motor	−1.00 (−7.5 to 2.5)	36 % (16/45)	0.003*	−1.30 (−7.5 to 2.2)	−1.00 (−3.4 to 2.5)	0.19
Static balance	−0.25 (−3.0 to 1.7)	17 % (8/46)	0.007*	−0.20 (−3.0 to 0.6)	−0.30 (−3.0 to 1.7)	0.84
Associated movements	−1.10 (−3.2 to 2.0)	38 % (18/47)	<0.001*	−1.25 (−3.2 to 0.2)	−0.90 (−2.3 to 2.0)	0.10

*Significant difference at $p < 0.05$

Results are presented as the median z -score with the range in parenthesis

^a Motor performance was assessed using the Zurich Neuromotor Assessment (ZNA)

^b <P10 indicates the proportion of patients presenting with z -scores of <−1.282 (i.e. results <10th percentile)

^c p value calculated for z -score difference to norm

^d p value calculated for z -score difference between patients with and without CNS involvement

When participants with additional neurodevelopmental comorbidities were excluded, the neurodevelopmental outcome compared to normal controls was still impaired except for the pure motor and the adaptive fine motor domain ($p > 0.07$). Participants with a history of ESRD ($n=5$) had significantly poorer results in the domain static balance than those without ESRD [−1.9 (range −3.0 to −0.7) vs. −0.2 (−3.0 to 1.7); $p = 0.003$].

Motor therapies (including psychomotor, physical and ergotherapy) were reported for nine children (19 %). There were no significant differences between children with and without CNS involvement in terms of frequency of motor therapies (6/31 vs. 3/16, respectively; $p = 0.64$).

Neurodevelopmental outcome in children with STEC-HUS

Table 6 presents the developmental outcome for children with only STEC-HUS—which was the commonest HUS form present in the study cohort ($n=38$). Compared to normal controls, children with STEC-HUS showed a favorable intellectual outcome. In contrast, neuromotor outcome was impaired in the ZNA domains “adaptive gross motor” and “associated movements”. In these domains, 34 % and 39 % respectively performed poorer than the 10th percentile (Table 6).

Prognostic factors

Potential risk factors for poorer IQ were evaluated in a multivariate linear regression analysis. Socioeconomic status ($\beta = 0.474$, $p = 0.001$) was the only factor associated with the full-scale IQ whereas CNS involvement ($\beta = -0.074$, $p = 0.62$), duration of hospital stay ($\beta = -0.257$, $p = 0.08$) and eGFR at time of discharge ($\beta = -0.117$, $p = 0.41$) were not.

Discussion

The majority of follow-up studies of children with HUS have focused on renal outcome after HUS episode [2–5, 9, 15]. Data on neurodevelopmental outcome, however, are scarce, with only few published studies of various designs and case series available [18, 30], and little information on long-term

Table 6 Neurodevelopmental outcome of 38 children with STEC-HUS

Assessment tool	Neurodevelopmental outcome		
	Score	p value	<P10 ^a
<i>Wechsler Intelligence Scale 4th version</i>			
Full-scale IQ	104.5 (82–127)	0.003*	
Verbal comprehension index	104 (79–124)	0.10	
Perceptual reasoning index	108 (86–123)	0.001*	
Working memory index	102 (82–135)	0.06	
Processing speed index	100 (79–129)	0.25	
<i>Zurich Neuromotor Assessment</i>			
Timed performances			
Pure motor	0.1 (−2.4 to 4.6)	0.91	11 % (4/38)
Adaptive fine motor	−0.3 (−3.6 to 3.5)	0.18	24 % (9/38)
Adaptive gross motor	−0.8 (−7.5 to 2.5)	0.012*	34 % (13/38)
Static balance	−0.2 (−2.9 to 1.7)	0.13	11 % (4/38)
Associated movements	−1.2 (−3.2 to 2.0)	<0.001*	39 % (15/38)

*Significant difference at $p < 0.05$

Results are presented as the median score with the range given in parenthesis. Comparison is to test norms (mean IQ 100, standard deviation 15)

STEC-HUS, *Escherichia coli* hemolytic uremic syndrome

^a <P10 indicates the proportion of patients presenting with z -scores of <−1.282 (i.e. results <10th percentile)

outcome. We report here our results from a single-center cross-sectional investigation assessing neurocognitive and neuromotor long-term outcome of pediatric patients after STEC-HUS, P-HUS or aHUS. In our study we also examined the role of CNS involvement during the acute episode of HUS on subsequent neurodevelopment. In contrast to previous studies focusing on STEC-HUS [17–19], we expressly included patients with different HUS forms (STEC-HUS, P-HUS and aHUS) even though apart from thrombotic microangiopathy the underlying pathomechanisms of these HUS forms do differ.

Our patient series showed an overall favorable neurodevelopmental outcome after a history of HUS, with a normal full-scale IQ. Furthermore, the intellectual performance of our patients was not affected by CNS impairment during the acute HUS episode. Only socioeconomic status was positively correlated with full-scale IQ, which is consistent with findings in healthy controls [26]. Socioeconomic status is also a strong predictor of intellectual outcome in other populations at risk, such as preterm born children [31] or children with congenital heart defects [32].

One-third of our study patients presented with neurological symptoms during the acute episode of HUS, particularly in the form of seizures and altered consciousness, including four of the six patients with P-HUS, but none of those with aHUS. These findings are consistent with those of previous studies on neurological involvement in patients with STEC-HUS (19–30 % showing neurological symptoms) [2, 9, 33] and P-HUS patients (16–56 % with neurological symptoms) [14, 34, 35]. There are no evidence-based guidelines on the treatment of CNS complications in HUS. Nathanson et al. [16] suggested that plasmapheresis might have some benefit in children with severe CNS complications. In our series, only two children with STEC-HUS underwent plasmapheresis for severe neurological complications with full neurological recovery.

Our findings are consistent with the results of three previous studies. Schlieper et al. [17] demonstrated a favorable neurocognitive outcome in children at a mean age of 8.6 years (± 3.1 SD) and mean duration of 4.1 years (± 2.4 SD) after the diagnosis of HUS, with normal full-scale and subscale IQ values in 91 children after HUS (without specification of HUS type), including nine children with seizures or coma during the acute episode of HUS. However, these authors did not observe mild deficits in language domains in patients with severe acute HUS [17]. Qamar et al. [18] described a normal intellectual outcome in all seven patients studied despite severe neurological complications during the acute disease. Bauer et al. [19] also reported a favorable neurocognitive outcome in 25 children affected by the STEC-HUS outbreak in 2011 in Germany due to *E. coli* O104:H4. However, these authors observed a slightly lower full-scale IQ in children with CNS involvement vs. those without CNS involvement during HUS. Other studies focusing on neurological involvement in

adult patients with STEC-HUS due to *E. coli* O104:H4 also suggested a good neurological outcome [36].

In our series, only six children (12 %), including four with ESRD, had a full-scale IQ of <85 , indicating an unfavorable intellectual outcome. Moreover, two of these six children had a history of severe cerebral complications after P-HUS.

Patients with a history of ESRD showed a significant poorer neurocognitive outcome after HUS compared to patients without ESRD after HUS. The development of ESRD, particularly in infancy, is a known risk factor for impaired neurocognitive outcome [37].

In our study, neuromotor performance was less favorable than intellectual outcome, with a poorer outcome particularly in fine and gross motor functioning, static balance and movement quality. Normal performance observed in the domain of pure motor functioning. This is an interesting finding. In this domain, simple motor tasks, such as repetitive or sequential finger, hand or foot movements, are performed. It is conceivable that impairments only become apparent when more complex motor functions, such as adaptive motor performances, are required. Motor performance did not differ between children with and without CNS impairment during acute HUS episode. Qamar et al. [18] also studied neuromotor outcome after HUS, reporting impaired fine motor and clumsiness in four of seven patients with severe neurological complications during the acute HUS episode. In our study, a significant proportion of patients (15–38 %) had motor performance below the 10th percentile. This poorer motor performance is clinically significant as children who perform below the 10th percentile often have difficulties participating in activities of daily life and demonstrate poorer hand writing skills and slower speed. However, we did not assess the impact of motor difficulties on daily life. Of note, motor therapies were reported in 19 % of our patients independently of CNS involvement during HUS.

The pathophysiological mechanisms leading to impaired neuromotor outcome after HUS remain to be clarified. In addition to cerebral thrombotic microangiopathy, factors such as electrolyte imbalances (e.g. severe hyponatremia), hypo-osmolality, azotemia, arterial hypertension and the direct toxic effects of Shiga toxin in STEC-HUS may be involved in pathogenetic mechanisms of neurological impairment [19, 38]. Impaired neuromotor outcome can also be found in other cohorts of pediatric patients with various diseases, such as congenital diaphragmatic hernia [39] or congenital heart disease [40]. Impaired neuromotor findings also suggest disease-unrelated factors leading to an adverse neuromotor performance, such as factors attributable to long hospital stay secondary to more severe course of a disease or more parental protection and less experience.

This study has several limitations. Due to its retrospective and cross-sectional study design, information on neurological complications during the acute illness phase was obtained

retrospectively by chart review and parental interviews. Apart from the parents' medical report, no formalized data on the neurodevelopmental status prior to HUS were available. Furthermore, the number of patients with P-HUS and aHUS was too small to analyze outcome in relation to HUS type.

In conclusion, the results of this study show that children and adolescents with HUS have a normal intellectual outcome, but a significant impairment in motor outcome. Neurological complications during the acute episode of HUS were not associated with a poorer neurodevelopmental outcome. Therefore, long-term observation of children after HUS is advisable for the early detection of neurodevelopmental deficits.

Acknowledgments We thank all the children, adolescents and their parents who participated in this study. We also thank Luciano Molinari, PhD, and Burkhardt Seifert, PhD, for support with the statistical analysis and Christina Schaefer, MD, University Children's Hospital Zurich, for performing the neurodevelopmental assessment. The honorarium of Kathrin Buder was supported by the Swiss Society of Nephrology and by the foundation "Kinder für Kinder".

Conflict of interest None.

References

- Andreoli SP (2009) Acute kidney injury in children. *Pediatr Nephrol* 24:253–263
- Schifferli A, von Vigier RO, Fontana M, Spatà G, Schmid H, Bianchetti MG, Rudin C, (SPSU) TSPSU (2010) Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997–2003. *Eur J Pediatr* 169:591–598
- Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. *JAMA* 290:1360–1370
- Copelovitch L, Kaplan BS (2008) *Streptococcus pneumoniae*-associated hemolytic uremic syndrome. *Pediatr Nephrol* 23:1951–1956
- Fremaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtsey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clin J Am Soc Nephrol* 8:554–562
- Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. *N Engl J Med* 361:1676–1687
- Loirat C, Saland J, Bitzan M (2012) Management of hemolytic uremic syndrome. *Presse Med* 41:e115–e135
- Scheiring J, Rosales A, Zimmerhackl LB (2010) Clinical practice. Today's understanding of the haemolytic uraemic syndrome. *Eur J Pediatr* 169:7–13
- Rosales A, Hofer J, Zimmerhackl L-B, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H, Group G-AHS (2012) Need for long-term follow-up in enterohemorrhagic *Escherichia coli*-associated hemolytic uremic syndrome due to late-emerging sequelae. *Clin Infect Dis* 54:1413–1421
- Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C, Slack MPE, Van't Hoff W, Dillon MJ, Taylor CM, Tullus K (2007) Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. *J Pediatr* 151:140–144
- Siegler RL (1994) Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. *J Pediatr* 125:511–518
- Scheiring J, Andreoli SP, Zimmerhackl LB (2008) Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). *Pediatr Nephrol* 23:1749–1760
- Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, Trachtman H (2004) Non-enteropathic hemolytic uremic syndrome: causes and short-term course. *Am J Kidney Dis* 43:976–982
- Brandt J, Wong C, Mihm S, Roberts J, Smith J, Brewer E, Thiagarajan R, Warady B (2002) Invasive pneumococcal disease and hemolytic uremic syndrome. *Pediatrics* 110:371–376
- Fitzpatrick MM, Walters MDS, Trompeter RS, Dillon MJ, Barratt TM (1993) Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood. *J Pediatr* 122:532–537
- Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Pietrement C, Champion G, Ulinski T, Deschenes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 5:1218–1228
- Schlieper A, Orbine E, Wells GA, Clulow M, McLaine PN, Rowe PC (1999) Neuropsychological sequelae of haemolytic uraemic syndrome. Investigators of the HUS Cognitive Study. *Arch Dis Child* 80:214–220
- Qamar IU, Ohali M, MacGregor DL, Wasson C, Krekewich K, Marcovitch S, Arbus GS (1996) Long-term neurological sequelae of hemolytic-uremic syndrome: a preliminary report. *Pediatr Nephrol* 10:504–506
- Bauer A, Loos S, Wehrmann C, Horstmann D, Donnerstag F, Lemke J, Hillebrand G, Lobel U, Pape L, Haffner D, Bindt C, Ahlenstiel T, Melk A, Lehnhardt A, Kemper MJ, Oh J, Hartmann H (2014) Neurological involvement in children with *E. coli* O104:H4-induced hemolytic uremic syndrome. *Pediatr Nephrol* 29:1607–1615
- Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, HUS EPRGf (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. *Kidney Int* 70:423–431
- Zipfel PF, Wolf G, John U, Kentouche K, Skerka C (2011) Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytopenic purpura? *Pediatr Nephrol* 26:1947–1956
- Barbour T, Johnson S, Cohney S, Hughes P (2012) Thrombotic microangiopathy and associated renal disorders. *Nephrol Dial Transplant* 27:2673–2685
- Wechsler D (2003) Manual for the Wechsler Intelligence Scale for Children. The Psychological Corporation, New York
- Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. *J Am Soc Nephrol* 20:629–637
- Hajnal BL, Sahebkar-Moghaddam F, Barnwell AJ, Barkovich AJ, Ferriero DM (1999) Early prediction of neurologic outcome after perinatal depression. *Pediatr Neurol* 21:788–793
- Largo RH, Pfister D, Molinari L, Kundu S, Lipp A, Duc G (1989) Significance of prenatal, perinatal and postnatal factors in the development of AGA preterm infants at five to seven years. *Dev Med Child Neurol* 31:440–456
- Wechsler D (2002) Wechsler Preschool and Primary Scale of Intelligence. The Psychological Corporation, San Antonio
- Largo RH, Cafilisch JA, Hug F, Muggli K, Molnar AA, Molinari L, Sheehy A, Gasser T (2001) Neuromotor development from 5 to 18 years. Part 1: timed performance. *Dev Med Child Neurol* 43:436–443

29. Largo RH, Caflisch JA, Hug F, Muggli K, Molnar AA, Molinari L (2001) Neuromotor development from 5 to 18 years. Part 2: associated movements. *Dev Med Child Neurol* 43:444–453
30. Steinborn M, Leiz S, Rüdiger K, Griebel M, Harder T, Hahn H (2004) CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings. *Pediatr Radiol* 34:805–810
31. Seitz J, Jenni OG, Molinari L, Caflisch J, Largo RH, Latal Hajnal B (2006) Correlations between motor performance and cognitive functions in children born <1250 g at school age. *Neuropediatrics* 37:6–12
32. von Rhein M, Dimitropoulos A, Valsangiacomo Buechel ER, Landolt MA, Latal B (2012) Risk factors for neurodevelopmental impairments in school-age children after cardiac surgery with full-flow cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 144:577–583
33. Cimolai N, Morrison BJ, Carter JE (1992) Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. *Pediatrics* 90:616–621
34. Banerjee R, Hersh AL, Newland J, Beekmann SE, Polgreen PM, Bender J, Shaw J, Copelovitch L, Kaplan BS, Shah SS (2011) *Streptococcus pneumoniae*-associated hemolytic uremic syndrome among children in North America. *Pediatr Infect Dis J* 30:736–739
35. Chen S-Y, Wu C-Y, Tsai I-J, Tsau Y-K, Su Y-T (2011) Nonenteropathic hemolytic uremic syndrome: the experience of a medical center. *Pediatr Neonatol* 52:73–77
36. Magnus T, Rother J, Simova O, Meier-Cillien M, Repenthin J, Moller F, Gbadamosi J, Panzer U, Wengenroth M, Hagel C, Kluge S, Stahl RK, Wegscheider K, Urban P, Eckert B, Glatzel M, Fiehler J, Gerloff C (2012) The neurological syndrome in adults during the 2011 northern German *E. coli* serotype O104:H4 outbreak. *Brain* 135: 1850–1859
37. Johnson RJ, Warady BA (2013) Long-term neurocognitive outcomes of patients with end-stage renal disease during infancy. *Pediatr Nephrol* 28:1283–1291
38. Donnerstag F, Ding X, Pape L, Bültmann E, Lücke T, Zajacsek J, Hoy L, Das AM, Lanfermann H, Ehrich J, Hartmann H (2012) Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement. *Eur Radiol* 22:506–513
39. Tureczek I, Caflisch J, Moehrlen U, Natalucci G, Bernet V, Latal B (2012) Long-term motor and cognitive outcome in children with congenital diaphragmatic hernia. *Acta Paediatr* 101:507–512
40. Schaefer C, von Rhein M, Knirsch W, Huber R, Natalucci G, Caflisch J, Landolt MA, Latal B (2013) Neurodevelopmental outcome, psychological adjustment, and quality of life in adolescents with congenital heart disease. *Dev Med Child Neurol* 55(12):1143–1149